JP Morgan Chase
PLRX icon

JP Morgan Chase’s Pliant Therapeutics PLRX Stock Holding History

JP Morgan Chase’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$784K Sell
681,647
-180,176
-21% -$219K ﹤0.01% 4841
2026
Q1 		$1.01M Sell
861,823
-351,052
-29% -$443K ﹤0.01% 4608
2025
Q4 		$1.48M Sell
1,212,875
-917,614
-43% -$1.38M ﹤0.01% 4334
2025
Q3 		$3.15M Buy
2,130,489
+172,056
+9% +$263K ﹤0.01% 3741
2025
Q2 		$2.27M Buy
1,958,433
+1,477,336
+307% +$2.09M ﹤0.01% 3815
2025
Q1 		$649K Buy
481,097
+283,846
+144% +$1.72M ﹤0.01% 4619
2024
Q4 		$2.6M Buy
197,251
+148,039
+301% +$2.02M ﹤0.01% 3945
2024
Q3 		$552K Buy
49,212
+22
+0% +$275 ﹤0.01% 4833
2024
Q2 		$529K Sell
49,190
-9,138
-16% -$118K ﹤0.01% 4663
2024
Q1 		$869K Sell
58,328
-27,265
-32% -$450K ﹤0.01% 4447
2023
Q4 		$1.55M Buy
85,593
+3,747
+5% +$57K ﹤0.01% 4022
2023
Q3 		$1.42M Buy
81,846
+8,649
+12% +$150K ﹤0.01% 3819
2023
Q2 		$1.33M Buy
73,197
+51,970
+245% +$1.23M ﹤0.01% 3839
2023
Q1 		$565K Buy
21,227
+6,268
+42% +$178K ﹤0.01% 4420
2022
Q4 		$290K Sell
14,959
-22,012
-60% -$460K ﹤0.01% 4842
2022
Q3 		$772K Buy
36,971
+35,385
+2,231% +$677K ﹤0.01% 4192
2022
Q2 		$13K Sell
1,586
-14,169
-90% -$90.7K ﹤0.01% 5988
2022
Q1 		$110K Sell
15,755
-38,081
-71% -$389K ﹤0.01% 5462
2021
Q4 		$727K Buy
53,836
+37,268
+225% +$592K ﹤0.01% 4602
2021
Q3 		$280K Buy
16,568
+3,448
+26% +$73.2K ﹤0.01% 5056
2021
Q2 		$382K Sell
13,120
-16,570
-56% -$516K ﹤0.01% 4863
2021
Q1 		$1.17M Buy
29,690
+25,014
+535% +$812K ﹤0.01% 4108
2020
Q4 		$106K Buy
4,676
+793
+20% +$19.9K ﹤0.01% 4987
2020
Q3 		$92K Buy
+3,883
New +$97K ﹤0.01% 4731

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

JP Morgan Chase's PLRX Position: Q2 2026 in Review

JP Morgan Chase reduced its Pliant Therapeutics (PLRX) stake by 21% in Q2 2026, selling an estimated $219K and leaving 681,647 shares worth $784K. The position accounts for ﹤0.01% of the portfolio, ranked #4841.

JP Morgan Chase first reported a position in PLRX in Q3 2020 and has held it in 24 quarters since. The position peaked at $3.15M in Q3 2025. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • JP Morgan Chase held 681,647 shares of Pliant Therapeutics worth $784K as of Q2 2026.
  • JP Morgan Chase sold 180,176 Pliant Therapeutics shares in Q2 2026, an estimated $219K.
  • Pliant Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4841 holding.
  • JP Morgan Chase first reported a position in Pliant Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Pliant Therapeutics position peaked at $3.15M in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.